Woodmont Investment Counsel LLC Has $221,000 Position in Zoetis Inc. $ZTS

Woodmont Investment Counsel LLC lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 4.6% in the second quarter, HoldingsChannel.com reports. The firm owned 1,416 shares of the company’s stock after selling 69 shares during the period. Woodmont Investment Counsel LLC’s holdings in Zoetis were worth $221,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Simplicity Wealth LLC raised its holdings in shares of Zoetis by 385.1% in the 2nd quarter. Simplicity Wealth LLC now owns 8,291 shares of the company’s stock worth $1,293,000 after acquiring an additional 6,582 shares during the last quarter. Brown Miller Wealth Management LLC raised its stake in shares of Zoetis by 2.0% in the second quarter. Brown Miller Wealth Management LLC now owns 9,299 shares of the company’s stock worth $1,450,000 after purchasing an additional 178 shares during the last quarter. OLD National Bancorp IN boosted its position in shares of Zoetis by 1,589.5% during the second quarter. OLD National Bancorp IN now owns 33,671 shares of the company’s stock valued at $5,251,000 after buying an additional 31,678 shares during the last quarter. Highland Capital Management LLC lifted its stake in Zoetis by 5.3% during the 2nd quarter. Highland Capital Management LLC now owns 39,635 shares of the company’s stock valued at $6,181,000 after acquiring an additional 2,006 shares in the last quarter. Finally, Clarius Group LLC raised its holdings in shares of Zoetis by 6.3% in the second quarter. Clarius Group LLC now owns 4,554 shares of the company’s stock valued at $710,000 after purchasing an additional 268 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Analyst Ratings Changes

ZTS has been the subject of several research analyst reports. Stifel Nicolaus lowered shares of Zoetis from a “buy” rating to a “hold” rating and decreased their price target for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and cut their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research report on Saturday, September 27th. Finally, Piper Sandler raised their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Five equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Zoetis currently has an average rating of “Moderate Buy” and a consensus price target of $200.88.

Zoetis Price Performance

Zoetis stock opened at $145.39 on Tuesday. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $196.55. The company has a market cap of $64.43 billion, a price-to-earnings ratio of 25.02, a PEG ratio of 2.35 and a beta of 0.90. The firm’s fifty day moving average is $149.68 and its 200 day moving average is $154.90. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same period in the prior year, the company earned $1.56 EPS. The business’s revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.